{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:33:53Z","timestamp":1793712833569,"version":"4.6.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon the\u00a0coronavirus disease 2019 (COVID-19) vaccination remain to be clarified. Hence, we aimed to investigate the long-term chronological changes in SARS-CoV-2 specific IgG antibody, neutralizing antibody, and T cell responses during and after receiving the BNT162b2 vaccine. We performed serological, neutralization, and T cell assays among 100 hospital workers aged 22\u201373\u00a0years who received the vaccine. We conducted seven surveys up to 8\u00a0months after the second vaccination dose. SARS-CoV-2 spike protein-specific IgG (IgG-S) titers and T cell responses increased significantly following the first vaccination dose. The highest titers were observed on day 29 and decreased gradually until the end of the follow-up period. There was no correlation between IgG-S and T cell responses. Notably, T cell responses were detected on day 15, earlier than the onset of neutralizing activity. This study demonstrated that both IgG-S and T cell responses were detected before acquiring sufficient levels of SARS-CoV-2 neutralizing antibodies. These immune responses are sustained for approximately 6 to 10\u00a0weeks but not for 7\u00a0months or later following the second vaccination, indicating the need for the booster dose (i.e., third vaccination).<\/jats:p>","DOI":"10.1038\/s41598-022-19581-y","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T09:07:59Z","timestamp":1663146479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9\u00a0months longitudinal study"],"prefix":"10.1038","volume":"12","author":[{"given":"Junko S.","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moto","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Kamikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gohzoh","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mizoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugen","family":"Ujiie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"19581_CR1","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard (https:\/\/covid19.who.int\/)."},{"key":"19581_CR2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412\u20131423. https:\/\/doi.org\/10.1056\/NEJMoa2101765 (2021).","journal-title":"N. Engl. J. Med."},{"key":"19581_CR3","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/22221751.2021.1953403","volume":"10","author":"J Favresse","year":"2021","unstructured":"Favresse, J. et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg. Microbes Infect. 10, 1495\u20131498. https:\/\/doi.org\/10.1080\/22221751.2021.1953403 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"19581_CR4","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.jve.2021.100046","volume":"7","author":"S Zaffina","year":"2021","unstructured":"Zaffina, S. et al. Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers. J. Virus Erad. 7, 100046. https:\/\/doi.org\/10.1016\/j.jve.2021.100046 (2021).","journal-title":"J. Virus Erad."},{"key":"19581_CR5","doi-asserted-by":"publisher","first-page":"1861.e1861","DOI":"10.1016\/j.cmi.2021.07.042","volume":"27","author":"T Kageyama","year":"2021","unstructured":"Kageyama, T. et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin. Microbiol. Infect. 27, 1861.e1861\u20131861.e1865. https:\/\/doi.org\/10.1016\/j.cmi.2021.07.042 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"19581_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03653-6","author":"U Sahin","year":"2021","unstructured":"Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature https:\/\/doi.org\/10.1038\/s41586-021-03653-6 (2021).","journal-title":"Nature"},{"key":"19581_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.medj.2021.04.003","volume":"2","author":"S Kalimuddin","year":"2021","unstructured":"Kalimuddin, S. et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Medicine 2, 682\u2013688.e684. https:\/\/doi.org\/10.1016\/j.medj.2021.04.003 (2021).","journal-title":"Medicine"},{"key":"19581_CR8","doi-asserted-by":"publisher","first-page":"22848","DOI":"10.1038\/s41598-021-01930-y","volume":"11","author":"K Maeda","year":"2021","unstructured":"Maeda, K. et al. Correlates of neutralizing\/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. Sci. Rep. 11, 22848. https:\/\/doi.org\/10.1038\/s41598-021-01930-y (2021).","journal-title":"Sci. Rep."},{"key":"19581_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2021.09.013","author":"M Martinez-Gallo","year":"2021","unstructured":"Martinez-Gallo, M. et al. Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. Med. Clin. https:\/\/doi.org\/10.1016\/j.medcli.2021.09.013 (2021).","journal-title":"Med. Clin."},{"key":"19581_CR10","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N. Engl. J. Med."},{"key":"19581_CR11","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. USA 117, 7001\u20137003. https:\/\/doi.org\/10.1073\/pnas.2002589117 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"19581_CR12","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1038\/s41598-021-84733-5","volume":"11","author":"K Maeda","year":"2021","unstructured":"Maeda, K. et al. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Sci. Rep. 11, 5563. https:\/\/doi.org\/10.1038\/s41598-021-84733-5 (2021).","journal-title":"Sci. Rep."},{"key":"19581_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","volume":"27","author":"JE Ebinger","year":"2021","unstructured":"Ebinger, J. E. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 27, 981\u2013984. https:\/\/doi.org\/10.1038\/s41591-021-01325-6 (2021).","journal-title":"Nat. Med."},{"key":"19581_CR14","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s40121-021-00521-8","volume":"10","author":"S Jaganathan","year":"2021","unstructured":"Jaganathan, S. et al. Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals. Infect. Dis. Ther. 10, 2765\u20132776. https:\/\/doi.org\/10.1007\/s40121-021-00521-8 (2021).","journal-title":"Infect. Dis. Ther."},{"key":"19581_CR15","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84. https:\/\/doi.org\/10.1056\/NEJMoa2114583 (2021).","journal-title":"N. Engl. J. Med."},{"key":"19581_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab381","author":"L Muller","year":"2021","unstructured":"Muller, L. et al. Age-dependent immune response to the Biontech\/Pfizer BNT162b2 COVID-19 vaccination. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab381 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"19581_CR17","doi-asserted-by":"publisher","first-page":"E257","DOI":"10.1002\/ajh.26185","volume":"96","author":"E Terpos","year":"2021","unstructured":"Terpos, E. et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am. J. Hematol. 96, E257\u2013E259. https:\/\/doi.org\/10.1002\/ajh.26185 (2021).","journal-title":"Am. J. Hematol."},{"key":"19581_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/oxfimm\/iqab006","author":"A Bertoletti","year":"2021","unstructured":"Bertoletti, A., Tan, A. T. & Le Bert, N. The T-cell response to SARS-CoV-2: Kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunol. https:\/\/doi.org\/10.1093\/oxfimm\/iqab006 (2021).","journal-title":"Oxford Open Immunol."},{"key":"19581_CR19","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","volume":"34","author":"AT Tan","year":"2021","unstructured":"Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728. https:\/\/doi.org\/10.1016\/j.celrep.2021.108728 (2021).","journal-title":"Cell Rep."},{"key":"19581_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417\u2013422. https:\/\/doi.org\/10.1038\/s41586-021-03739-1 (2021).","journal-title":"Nature"},{"key":"19581_CR21","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3825573","author":"HM Parry","year":"2021","unstructured":"Parry, H. M. et al. Single vaccination with BNT162b2 or ChAdOx1 in older people induces equivalent antibody generation but enhanced cellular responses after ChAdOx1. SSRN Electron. J. https:\/\/doi.org\/10.2139\/ssrn.3825573 (2021).","journal-title":"SSRN Electron. J."},{"key":"19581_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.abd3871","volume":"370","author":"J Mateus","year":"2020","unstructured":"Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89\u201394. https:\/\/doi.org\/10.1126\/science.abd3871 (2020).","journal-title":"Science"},{"key":"19581_CR23","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e1415. https:\/\/doi.org\/10.1016\/j.cell.2020.05.015 (2020).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19581-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T09:42:43Z","timestamp":1663148563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19581-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19581"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19581-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.06.21265632","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors (except Gohzoh Ueda) declare no conflict of interest. Gohzoh Ueda is one of employees of Abbott Japan, which provided the antibody assay reagents and funding for the present study. The funders did not play any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15447"}}